Track topics on Twitter Track topics that are important to you
Athersys’ stock has gained 25% in the last month to trade at an 18-month high. We believe positive biotech sentiment in general, and burgeoning interest in stem cells and regenerative medicine in particular, are contributory factors. For Athersys, the key near-term catalyst is headline data in Q413 from a Phase II study of its MultiStem product (allogeneic stem cells from adult bone marrow) for ulcerative colitis (UC), conducted by partner Pfizer. Positive results would provide important clinical validation of MultiStem and help to de-risk other opportunities.
Source: Edison Investment - Read full review at http://www.edisoninvestmentresearch.co.uk/NEXT ARTICLE
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...